癌症。沉默代谢致癌基因。
Cancer. Silencing a metabolic oncogene.
机构信息
Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
出版信息
Science. 2013 May 3;340(6132):558-9. doi: 10.1126/science.1238523.
Abstract
Small molecules inhibit a mutant enzyme confined to tumors, supporting therapeutic approaches that can reprogram metabolism in cancer.
摘要
小分子抑制局限于肿瘤的突变酶，为重新编程癌症代谢的治疗方法提供支持。
相似文献
1
Cancer. Silencing a metabolic oncogene.
Science. 2013 May 3;340(6132):558-9. doi: 10.1126/science.1238523.
2
Therapeutics: targeting an oncometabolite.
Nat Rev Cancer. 2013 Jun;13(6):383. doi: 10.1038/nrc3531. Epub 2013 May 3.
3
Cancer metabolism in breadth and depth.
Nat Biotechnol. 2013 Jun;31(6):505-7. doi: 10.1038/nbt.2611.
4
Releasing the block: setting differentiation free with mutant IDH inhibitors.
Cancer Cell. 2013 May 13;23(5):570-2. doi: 10.1016/j.ccr.2013.04.024.
5
[(R)-2-hydroxyglutarate or (R)-2HG is an oncometabolite].
Bull Cancer. 2013 Jul-Aug;100(7-8):655.
6
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.
7
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.
8
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Science. 2013 Mar 29;339(6127):1621-5. doi: 10.1126/science.1231677. Epub 2013 Feb 7.
9
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Oncotarget. 2016 Nov 29;7(48):79722-79735. doi: 10.18632/oncotarget.12944.
10
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
J Neurochem. 2015 Jan;132(2):183-93. doi: 10.1111/jnc.12950. Epub 2014 Nov 2.
引用本文的文献
1
State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431450. doi: 10.1200/EDBK_431450.
2
Pheochromocytoma: Gasping for Air.
Horm Cancer. 2015 Dec;6(5-6):191-205. doi: 10.1007/s12672-015-0231-4. Epub 2015 Jul 3.
3
Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
Cell Cycle. 2014;13(5):699-709. doi: 10.4161/cc.28079. Epub 2014 Feb 3.
4
Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Biomed Res Int. 2014;2014:735659. doi: 10.1155/2014/735659. Epub 2014 Jan 9.
5
Oncometabolites: linking altered metabolism with cancer.
J Clin Invest. 2013 Sep;123(9):3652-8. doi: 10.1172/JCI67228. Epub 2013 Sep 3.
6
The phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2)-dependent Tup1 conversion (PIPTC) regulates metabolic reprogramming from glycolysis to gluconeogenesis.
J Biol Chem. 2013 Jul 12;288(28):20633-45. doi: 10.1074/jbc.M113.452813. Epub 2013 Jun 3.
本文引用的文献
1
Evidence for two distinct populations of type Ia supernovae.
Science. 2013 Apr 12;340(6129):170-3. doi: 10.1126/science.1231502. Epub 2013 Mar 7.
2
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Science. 2013 Mar 29;339(6127):1621-5. doi: 10.1126/science.1231677. Epub 2013 Feb 7.
3
Progress in understanding 2-hydroxyglutaric acidurias.
J Inherit Metab Dis. 2012 Jul;35(4):571-87. doi: 10.1007/s10545-012-9462-5. Epub 2012 Mar 6.
4
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.
5
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.
6
A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG.
Biochemistry. 2011 May 31;50(21):4804-12. doi: 10.1021/bi200499m. Epub 2011 May 4.
7
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Cancer Cell. 2011 Jan 18;19(1):17-30. doi: 10.1016/j.ccr.2010.12.014.
8
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Cancer Cell. 2010 Dec 14;18(6):553-67. doi: 10.1016/j.ccr.2010.11.015. Epub 2010 Dec 9.
9
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 2009 Dec 10;462(7274):739-44. doi: 10.1038/nature08617.
10
IDH1 and IDH2 mutations in gliomas.
N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.
Zotero 插件